Medication info
Piotmin Tablet 15/850 mg

Piotmin Tablet 15/850 mg

Prescription medicationTablet
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Hubist Pharmaceutical Co., Ltd.
Appearance
White to grayish-white oblong film-coated tablet
Packaging
30 tablets (10 tablets/PTP*3)
Approval status
Active

MFDS item code 201802894 · Approved 2018.07.11 · Insurance code 628801150

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this drug once daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this drug may start at their existing doses of pioglitazone and metformin. No studies have been conducted to assess the safety and efficacy of switching from another oral antihyperglycemic agent to this drug. Any change in a type 2 diabetes treatment regimen may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this drug. Patients should be carefully monitored for adverse reactions associated with fluid retention after starting this drug or increasing the dose. This drug should generally be administered in divided doses with meals; doing so may reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Ingredients

Manufacturer
Hubist Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar levels in patients with Type 2 diabetes. It is designed to manage blood sugar levels effectively by supporting dietary and exercise regimens through the combined use of Pioglitazone and Metformin. This helps improve diabetes management and reduces the risk of complications.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this drug once daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this drug may start at their existing doses of pioglitazone and metformin. No studies have been conducted to assess the safety and efficacy of switching from another oral antihyperglycemic agent to this drug. Any change in a type 2 diabetes treatment regimen may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this drug. Patients should be carefully monitored for adverse reactions associated with fluid retention after starting this drug or increasing the dose. This drug should generally be administered in divided doses with meals; doing so may reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Precautions

This medication helps lower blood sugar levels. However, it can rarely cause a serious condition known as lactic acidosis, which can occur when lactate builds up excessively in the body and can be dangerous. The risk of lactic acidosis increases, especially in patients with impaired kidney function, heart or lung problems, dehydration, or infections. Additionally, patients with impaired liver function should avoid using this medication, and excessive alcohol consumption can increase the risk of lactic acidosis, so alcohol should be avoided. This medication should not be used in patients with severely reduced heart function, and if symptoms of heart failure occur, you should consult a doctor immediately. Patients with a history of bladder cancer or current bladder cancer should also avoid using this medication. Women who are pregnant or breastfeeding should not use this medication, and the safety of this medication in pediatric patients has not been established. Elderly patients are likely to have impaired kidney function, so the dosage of this medication should be carefully adjusted, and kidney function should be regularly monitored. During treatment with this medication, regular blood sugar and kidney function tests, liver function tests, and blood tests should be conducted, and if any abnormal symptoms occur, you should inform your doctor immediately. If severe vomiting, diarrhea, dehydration, acute illness, or other issues arise, temporary suspension of this medication should be discussed with healthcare professionals. Furthermore, since there may be interactions with other medications, inform your healthcare provider of all medications you are taking, especially those affecting the kidneys or lowering blood sugar levels. Symptoms of hypoglycemia or lactic acidosis may present, so symptoms should be carefully monitored, and if abnormalities occur, consult your healthcare provider immediately. It is also recommended to maintain regular meals and appropriate exercise during treatment with this medication, and to limit alcohol consumption for safety.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • upper respiratory tract infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
Show 22 more
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorder
  • worsening diabetes
  • pharyngitis
  • anemia
  • decreased vision
  • liver failure
  • congestive heart failure
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • intragastric air retention
  • increased serum creatinine
  • increased serum urea
  • macular edema
  • fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

White to grayish-white oblong film-coated tablet

Package unit

30 tablets (10 tablets/PTP*3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.